1. Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T- Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback (IND 14359) 
Cori Abikoff, MD, Julie-An Talano, MD, Carolyn Keever-Taylor, PhD, Mark Walters, MD, Shalini Shenoy, MD, Theodore B. Moore, MD, Susan K. Parsons, MD, MRP, Allen J. Dozor, MD, Deborah Friedman, MD, Ramanamoorthy Chitti, MD, Qiuhu Shi, PhD, Brenda Grossman, MD, Rona Weinberg, PhD, Erin Morris, RN, BSN, Phyllis Brand, RN, MPH, Sandra Fabricatore, RN, MSN, CPNP, Olga Militano, PharmD, Janet Ayello, MS, MT(ASCP), Mildred Semidei-Pomales, MS, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 2, Pages S90-S91 (February 2015)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Childhood and Adolescent and Young Adult Familial Haploidentical AlloSCT Sickle Cell Disease Consortium.
Biology of Blood and Marrow Transplantation  , S90-S91DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2 Patient Outcomes.
Biology of Blood and Marrow Transplantation  , S90-S91DOI: ( /j.bbmt )
Copyright © Terms and Conditions